This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?
by Zacks Equity Research
Impressive performance by the PBM unit is likely to drive Express Scripts' (ESRX) Q1 earnings.
Will Global Industrial Unit Boost Ecolab's (ECL) Q1 Earnings?
by Zacks Equity Research
Solid prospects in Global Industrial, Global Energy and Global Institutional segments are likely to drive Ecolab's (ECL) Q1 earnings.
Can Business Services Aid athenahealth's (ATHN) Q1 Earnings?
by Zacks Equity Research
athenahealth's (ATHN) strong product portfolio, network expansion strategies and unique business model are likely to drive Q1 earnings.
4 MedTech Stocks to Keep in Good Books This Earnings Season
by Zacks Equity Research
Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.
Here's Why Teleflex Has Been Losing Ground Since Q4 Earnings
by Zacks Equity Research
Teleflex's (TFX) contracted Q4 adjusted operating margin is discouraging.
Teleflex (TFX), HealthTrust Rebond on Respiratory Products
by Zacks Equity Research
Teleflex's (TFX) exclusive contracts with HealthTrust provide benefits to the latter with an opportunity to consolidate its members' respiratory purchases with the same supplier.
Key MedTech Trends to Influence Q3 Earnings: BDX, ABC, TFX
by Zacks Equity Research
Here we take a look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe this season.
Should You Buy Teleflex (TFX) Ahead of Earnings?
by Zacks Equity Research
Teleflex (TFX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Teleflex (TFX) Hits a 52-Week High on NeoTract Acquisition
by Zacks Equity Research
NeoTract acquisition is expected to generate mid-single digit constant currency revenue growth for the next several years and enhance Teleflex's (TFX) margins.
Abiomed's Latest Regulatory Progress Boosts Impella Line
by Zacks Equity Research
We believe that robust demand for Impella products will continue to drive Abiomed's (ABMD) top line over the long term.
Top Ranked Momentum Stocks to Buy for September 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 21st:
Orthofix (OFIX) is a Great Momentum Pick for You: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, Orthofix (OFIX) stands out as one of the most suitable momentum stock.
Can Myriad Genetics (MYGN) Spring a Surprise in Q4 Earnings?
by Zacks Equity Research
Myriad Genetics (MYGN) is well poised to deliver favorable results in Q4 riding on a diversified portfolio with products like Vectra DA test.
Can CVS Health (CVS) Pull a Surprise this Earnings Season?
by Zacks Equity Research
CVS Health (CVS) is poised to gain on strong Pharmacy Services numbers that benefited from the upside in Specialty Pharmacy in Q2.
Why Earnings Season Could Be Great for Teleflex Incorporated (TFX)
by Zacks Equity Research
Teleflex Incorporated (TFX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
MedTech Stocks to Top Q2 Estimates
by Zacks Equity Research
Most of the MedTech majors are lined up to report their earnings results over the next week.
What's in the Cards for DaVita (DVA) this Earnings Season?
by Zacks Equity Research
Despite a stable Kidney Care business, escalating expenses is likely to mar DaVita's (DVA) performance in the second quarter.
Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock?
by Zacks Equity Research
Lower TAVR sales due to recall of Lotus valves within the European and other key markets is likely to mar Boston Scientific's (BSX) top-line performance in Q2.
LabCorp (LH) Q2 Earnings: Is Disappointment in the Cards?
by Zacks Equity Research
With the Covance Drug Diagnostic arm's revenue and margins projected to decline further, LabCorp???s business in Q2 might face disruption.
What's in Store for athenahealth (ATHN) in Q2 Earnings?
by Zacks Equity Research
athenahealth Inc. (ATHN) is set to report second-quarter 2017 results on Jul 20.
Will Intuitive Surgical (ISRG) Surprise in Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20.
Will Thermo Fisher's (TMO) Q2 Earnings Surpass Expectations?
by Zacks Equity Research
Strong focus on product launch and emerging market expansion should drive Thermo Fisher (TMO) toward an earnings beat in Q2.
Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report second-quarter 2017 results before the opening bell on Jul 20.
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
Teleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris
by Zacks Equity Research
Teleflex Inc. (TFX) announced plans to introduce Arrow AC3 Optimus Intra-Aortic Balloon Pump at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) in Paris during May 16--19.